The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
The company discontinues one of its two KRAS G12D degraders.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
After a phase 3 push the livmoniplimab plan falters.
With a slashed valuation the newly listed biotech heads for phase 3.
